We are live on ! Find out more
ERNA icon

Eterna Therapeutics
ERNA

9 hedge funds and large institutions have $728K invested in Eterna Therapeutics in 2023 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.02% → 0.02% (-0%)

3% less capital invested

Capital invested by funds: $750K → $728K (-$21.8K)

10% less funds holding

Funds holding: 10 → 9 (-1)

25% less repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
9
Holders Change
-1
Holders Change %
-10%
% of All Funds
0.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Geode Capital Management
Geode Capital Management
Massachusetts
+$21.2K
2
SCA
Sippican Capital Advisors
Massachusetts
+$15.7K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$13.8K

Top Sellers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
-$25.5K
2
Corient Private Wealth
Corient Private Wealth
Florida
-$22.1K
3
BlackRock
BlackRock
New York
-$2.76K
4
NW
Naviter Wealth
Arkansas
-$2.76K
5
TRCT
Tower Research Capital (TRC)
New York
-$921
Name Holding Trade Value Shares
Change 		Change in
Stake
CPWM
1
Cypress Point Wealth Management
Texas
$206K – – –
NW
2
Naviter Wealth
Arkansas
$173K -$2.76K -3 -1%
Corient Private Wealth
3
Corient Private Wealth
Florida
$116K -$22.1K -24 -15%
SCA
4
Sippican Capital Advisors
Massachusetts
$61.3K +$15.7K +17 +29%
Vanguard Group
5
Vanguard Group
Pennsylvania
$54.3K +$13.8K +15 +29%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$50.9K +$21.2K +23 +62%
BlackRock
7
BlackRock
New York
$36.1K -$2.76K -3 -6%
BWP
8
Baldwin Wealth Partners
Massachusetts
$20.6K – – –
TRCT
9
Tower Research Capital (TRC)
New York
$10K -$921 -1 -8%
UBS Group
10
UBS Group
Switzerland
$229 – – –
MA
11
Montag & Associates
Georgia
$153 – – –
Morgan Stanley
12
Morgan Stanley
New York
$109 – – –
Wells Fargo
13
Wells Fargo
California
$57 – – –
Group One Trading
14
Group One Trading
Illinois
$43 – – –
Citigroup
15
Citigroup
New York
$34 – – –
PWA
16
Provenance Wealth Advisors
Florida
$33 – – –
JP Morgan Chase
17
JP Morgan Chase
New York
$32 – – –
APC
18
Aspire Private Capital
North Carolina
$21 – – –
Qube Research & Technologies (QRT)
19
Qube Research & Technologies (QRT)
United Kingdom
$9 – – –
Fidelity Investments
20
Fidelity Investments
Massachusetts
$2 – – –
Goldman Sachs
21
Goldman Sachs
New York
– -$25.5K -30 Closed
CHA
22
Carmichael Hill & Associates
Maryland
– -$170 – –

ERNA Hedge Fund Activity: Q3 2023 in Review

9 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2023, worth a combined $728K — down 2.9% from $750K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of ERNA and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 3 added.

The largest buyer was Geode Capital Management, adding an estimated $21.2K. The largest seller was Goldman Sachs, exiting entirely with an estimated $25.5K sold.

  • 9 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2023, down from 10 in Q2 2023.
  • Funds reported $728K of Eterna Therapeutics stock for Q3 2023, down 2.9% quarter-over-quarter.
  • 0 funds opened new Eterna Therapeutics positions in Q3 2023 and 1 closed out, a net change of -1 holder.
  • The largest Eterna Therapeutics buyer in Q3 2023 was Geode Capital Management, an estimated $21.2K added.
  • The largest Eterna Therapeutics seller in Q3 2023 was Goldman Sachs, an estimated $25.5K sold.

Based on aggregated 13F filings for Q3 2023.